ReviewSeminars in oncology2011
The use of genomic information to optimize cancer chemotherapy.
Review in Seminars in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Engineering CRISPR/Cas9 therapeutics for cancer precision medicine.Frontiers in genetics · 2024Review
- Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.International journal of molecular sciences · 2022Article
- The PLCE1 rs2274223 variant is associated with the risk of laryngeal squamous cell carcinoma.International journal of medical sciences · 2020Observational
- Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells.Molecular systems biology · 2018Article
- Needles, Haystacks and Next-Generation Genetic Sequencing.Health matrix (Cleveland, Ohio : 1991) · 2018Article
- Lessons Learned From Past Gene-Environment Interaction Successes.American journal of epidemiology · 2017Review
- Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).Journal of the National Cancer Institute · 2015Observational
- Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.Public health genomics · 2015Review
- Article
- Oxidative stress, prooxidants, and antioxidants: the interplay.BioMed research international · 2014Review
- Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?Pharmacogenomics · 2013Article
- Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Biomarkers in medicine · 2012Review
- A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Approach to epigenetic analysis in language disorders.Journal of neurodevelopmental disorders · 2011Article
- Recent progress and clinical importance on pharmacogenetics in cancer therapy.Clinical chemistry and laboratory medicine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The field of pharmacogenomics is focused on the characterization of genetic factors contributing to the response of patients to pharmacological interventions. Drug response and toxicity are complex traits; therefore the effects are likely influenced by multiple genes. The investigation of the genetic basis of drug response has evolved from a focus on single genes to relevant pathways to the entire genome. Preclinical (cell-based models) and clinical genome-wide association studies (GWAS) in oncology provide an unprecedented opportunity for a comprehensive and unbiased assessment of the heritable factors associated with drug response. The primary challenge with attempting to identify pharmacogenomic markers from clinical studies is that they require a homogeneous population of patients treated with the same dosage regimen and minimal confounding variables. Therefore, the development of cell-based models for pharmacogenomic marker identification has utility for the field since performing these types of studies in humans is difficult and costly. This review intends to provide a current report on the status of genomic studies in oncology, the methods for discovery, and implications for patient care. We present a perspective and summary of the challenges and opportunities in translating heritable genomic discoveries to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.